The contaminant has been linked to the deaths of more than 300 children in Africa and Asia
Gilead prices COVID-19 drug candidate remdesivir at $390 per vial in US
Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at $390 per vial in the United States and other developed countries.
Published : 29 June 2020, 11:38 AM
Updated : 29 June 2020, 11:38 AM
Based on current treatment patterns, the vast majority of patients are expected to receive a five-day treatment course using six vials of remdesivir, which equates to $2,340 per patient, the company said.
RELATED STORIES
The last time fatality from the disease was recorded on Apr 13
DRAP sent suspect drums of propylene glycol, a sweet-tasting alcohol used in over-the-counter medicines such as cough syrups, for testing
Chinese scientists last year suggested raccoon dogs may also have been involved in coronavirus reaching humans
